Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
P/S ratio for Lipella Pharmaceuticals Inc. (LIPO)
P/S ratio as of 2023: 108.95
According to Lipella Pharmaceuticals Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 108.95. At the end of 2022 the company had a P/S ratio of 781.01.
P/S ratio history for Lipella Pharmaceuticals Inc. from 2019 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 108.95 |
| 2022 | 781.01 |
| 2021 | 127.35 |
| 2020 | 34.04 |
| 2019 | 47.12 |